T2 Biosystems is an in vitro diagnostics company focused on developing diagnostic products and product candidates globally. The company's innovative technology detects pathogens, biomarkers, and other abnormalities in different patient sample types, enabling the diagnoses of severe health conditions such as sepsis and Lyme disease. Its portfolio includes various tests, including T2Candida, T2Bacteria, T2Resistance, T2SARS-CoV-2, T2Lyme, and T2Biothreat, as it collaborates with Canon U.S. Life Sciences, Inc., to develop a diagnostic test panel.